Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

More patients come forward with stories about the pains they've suffered since beginning Ozempic, joining a growing number of ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

The company's semaglutide injection—better known by the brand names Ozempic and Wegovy—has become well-known for its weight-loss results and ability to manage diabetes. And while there are several ...

The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...